Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion
Objective: To compare weight variations between three cohorts of patients with advanced Parkinson’s disease (PD): patients during their first year of treatment either with levodopa-carbidopa…Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study
Objective: To determine the effect and risk factors of a single dose levodopa induced OH in PD Background: Levodopa (LD) is widely recognised as the…Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…Subthalamic nucleus stimulation normalises effort-based decision-making in Parkinson’s disease
Objective: To compare the influence of levodopa and subthalamic nucleus stimulation (STN-DBS) on effort-based decision-making in Parkinson’s disease (PD). Background: Idiopathic PD is a neurodegenerative…Prevalence, Distribution and Management of Parkinson among Pakistani Population
Objective: To evaluate clinical spectrum and management of the parkinson disease(PD) among Pakistani population. Background: Parkinson, an idiopathic, slowly progressive neuro-degenerative syndrome characterized by bradykinesia,…The possibility of medicamentous correction of the lower urinary tract dysfunction in patients with Parkinson’s disease
Objective: The aim of the study was to correct the dyskinesia of the extremities, to study the efficacy and safety of drug therapy in men…Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion
Objective: To determine characteristics of parkinsonian patients under levodopa/carbidopa intestinal gel (LCIG) infusion who present impulse control disorders (ICDs). Background: ICDs may be induced by…Cerebral and pulmonary thromboembolism in a patient with hyperhomocystinemia treated with high dose levodopa/carbidopa intestinal gel
Objective: We report a case that developed cerebral and pulmonary thromboembolism during 24-hour levodopa/carbidopa intestinal gel (LCIG) infusion. Background: LCIG is a therapeutic option in…The hardest symptoms that bother patients with Parkinson’s disease before and 3 months after Deep brain stimulation and Continuous infusion of levodopa-carbidopa intestinal therapy
Objective: In this study we want to see what are the hardest and the most troublesome symptoms perceived by patients with Parkinson’s disease (PD) before…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 62
- Next Page »